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博士論文要旨 
 
近年、食生活の欧米化により糖尿病患者数は増加の一途を辿っており、その対策が急
務となっている。糖尿病は心疾患や脳血管障害に繋がる恐れがあり、食習慣の改善で解
決されない場合は、薬剤による血糖値のコントロールが必要となる。糖尿病に対する薬
剤の選択肢は幅広いが、根本治療は達成できておらず、新たな作用機序に基づく血糖値
制御因子の探索とその制御法の開発が望まれる。 
肝臓における糖新生は、空腹時に糖を合成することで血糖値を高める役割があり、血
糖値上昇要因の一つである。一方で、糖尿病患者では糖新生が恒常的に亢進しており、
糖新生を阻害する薬剤は血糖値を低下させる。糖新生はグルカゴン-cyclic AMP（cAMP）
シグナルにより制御されており、様々な酵素とその遺伝子の発現に関与する転写調節因
子が関与する。それに関連する転写調節因子の代表として、cAMP-response 
element-binding protein（CREB）やその共役因子(CREB regulated transcription 
coactivator 2, CRTC2)が挙げられる。 
塩誘導性キナーゼ（Salt Inducible Kinase, SIK）は CREB-CRTC2 を抑制するため、
SIK の活性化剤が糖尿病に有効であると予想される。SIKには３つのアイソフォームが
あり、これまでに、マウス肝臓の SIK1 タンパク質を欠損させると、血糖値が上昇する
ことが明らかにされている。さらに SIK2 も糖代謝において抑制的に機能していることが
報告されている。しかしながら、SIK3 の糖代謝における役割は未だ明らかにされていな
い。本研究では、SIK3 シグナル阻害剤を同定し、その阻害剤の SIK3 依存的・非依存的
な肝糖新生制御メカニズムの解明を行った。 
 
第１章：SIK3 遺伝子破壊マウスにおける SIK3 の糖新生における役割 
SIK3 遺伝子破壊マウス（SIK3-KO マウス）を用いて、SIK3 の糖代謝への影響を検討
した。SIK3-KOマウスは痩せ型であり、極度な低血糖を示すことが明らかとなった。し
かしながら、SIK3-KO マウスの肝臓における糖新生関連遺伝子の発現は有意に上昇して
いた。SIK3-KO マウスは痩せ型を示しているため、体内のエネルギー不足（空腹状態）
により二次的に糖新生が亢進している可能性が示唆された。そこで、二次的影響を除外
した条件下で SIK3 の糖新生における役割を確認するため、SIK3 による CRTC2 の遺伝
子発現の抑制を阻害する化合物（SIK3 シグナル阻害剤）の探索・同定を行った。SIK3
シグナル阻害剤は、遺伝子の活性を発光強度として観測することが出来るレポーターア
ッセイシステムを利用して探索・同定した。その結果、ワラビ成分である Pterosin B が
SIK3 シグナル阻害活性を示すことを判明し、その阻害によって糖新生関連酵素の遺伝子
発現を上昇させることを示した。すなわち、肝臓では SIK3 シグナルを阻害すると血糖値
上昇に繋がると示唆された。 
 
第２章：SIK3 シグナル阻害剤 Pterosin B を用いた SIK3 依存的な肝糖新生制御メカニ
ズムの解明 
第１章において同定した SIK3 シグナル阻害剤 Pterosin B を用いて、SIK3 依存的な糖
新生制御メカニズムの解明を行った。Pterosin B が SIK3 の直接阻害剤では無かったこ
とから、Pterosin B の作用部位としての SIK3 の上流因子を探索した。その結果、Pterosin 
B はグリコーゲンの分解を刺激するキナーゼ Phosphorylase kinase catalytic subunit 
gamma2 (PHKG2)の SIK3 ヘの結合性を上昇させ、SIK3 抑制ドメインのリン酸化を亢
進させることで SIK3 シグナルを阻害することが示唆された。以上の結果から、Pterosin 
B は PHKG2 を介して SIK3 を阻害し、肝臓における糖新生を亢進させることが示され、
SIK3 が肝糖新生において重要な役割を果たすことが示唆された。                                                                                                                                                                                                                                            
 
第３章：Pterosin B の SIK3 非依存的な肝糖新生制御メカニズムの解明 
第２章において、Pterosin B は SIK3 を介して肝糖新生を亢進させることが示された。
しかしながら、Pterosin B の類似体である Pterosin A は血糖値低下作用を有することが
報告されている。そこで、生体レベルにおける Pterosin B の血糖値への影響を検討する
ため、糖尿病モデルマウスに Pterosin B を混餌した飼料を与えたところ、コントロール
飼料群に比べて血糖値が低下しており、SIK3 阻害による糖新生亢進とは矛盾する結果と
なった。そこで、Pterosin B の糖新生における新たな役割の解明を行うことにした。単
離したマウス初代肝細胞を用いて、糖新生を亢進させるホルスコリン（Forskolin, Fsk）
存在下におけるグルコース産生実験を行った結果、Fsk により活性化した糖新生は、
Pterosin B により抑制されることが示された。さらに、マウス肝臓由来の培養細胞を用
いて、Fsk 依存的な糖新生関連遺伝子の発現亢進時における Pterosin B の影響を検討し
たところ、Pterosin B は糖新生の最終ステップ酵素 glcose-6-phosphatase（G6Pc）の発
現を抑制することが示された。これは、G6pc のプロモーターにおける Retinoic acid 
receptor-related orphan receptor alpha-steroid receptor coactivator 2 (RORα-SRC2)
複合体の結合阻害に起因していることがレポーターアッセイにより明らかとなった。さ
らに、Pterosin B はミトコンドリア呼吸鎖の Coenzyme Q の酸化還元サイクルに異常を
きたし、細胞内の ATP レベルを低下させることを示唆した。ミトコンドリア呼吸鎖複合
体 III の阻害剤 Antimycin A も Pterosin B と同様に、RORα-SRC2 複合体を阻害して
G6pc の遺伝子発現を抑制することが明らかとなり、RORα-SRC2 複合体はミトコンド
リア呼吸鎖の Coenzyme Q の酸化還元サイクル異常を感知して G6pc の発現を調節して
いる可能性が示唆された。以上の結果から、Pterosin B は G6pc への RORα-SRC2 複合
体の結合を阻害して、糖新生の最終ステップ G6Pc の発現を抑制することで血糖値を低下
させると結論した。 
            
以上          
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Introduction 
 
 
The number of patients suffering from lifestyle-related diseases, diabetes, 
hyperlipidemia, and hypertension have been increasing by the western lifestyles. Once 
lifestyle-related diseases are developed, a continuous medication is required.  
In the case of diabetes, the number of patients tends to increase from 470 million in 
1980 to over 2000 million in 2014. Seriously diabetic patients need insulin 
supplementation and some develop renal insufficiency followed by hemodialysis, 
resulting in a reduced quality of life. 
Diabetes is classified as type I and type II. Type I diabetes is due to a lack of insulin, 
therefore, patients in type I diabetes require insulin injection. On the other hand, type II 
diabetes is caused by a decrease of insulin secretion or insulin resistance. Patients in 
type II diabetes are prescribed medications to control blood glucose level.   
Blood glucose levels are maintained by a balance between glucose 
uptake/storage/utilization and glucose production, gluconeogenesis. Gluconeogenic 
program in hepatocytes is important for providing glucose to peripheral tissues under a 
fasting state. However, gluconeogenesis is up-regulated not only under fasting but also 
under feeding state in patients with diabetes, resulting in hyperglycemia.  
Hepatic gluconeogenesis is regulated by two rate-limiting enzymes, 
phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase catalytic 
subunit (G6PC). Gene expressions of these enzymes are up-regulated in patients with 
diabetes.  
5′-AMP-activated protein kinase (AMPK) is a serine/threonine kinase that function as 
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intracellular energy sensor. AMPK is activated under conditions that increase AMP 
levels such as glucose deprivation and excess exercise. Once activated, AMPK 
phosphorylates a number of downstream targets, resulting in the improvement of not 
only glucose metabolism but also lipid metabolism. Therefore, AMPK is considered to 
be a key therapeutic target for the treatment of metabolic diseases such as type II 
diabetes and obesity. Metformin used for the treatment of type II diabetes lowers 
blood glucose levels by regulation of hepatic gluconeogenesis via the activation of 
AMPK in an insulin-dependent manner, therefore hypoglycemia is rarely caused. 
However, it has been reported that not only metformin but also other therapeutic agents 
for diabetes have side effects. For example, metformin is contraindication to kidney 
diseases, because it is metabolized in the kidneys. Therefore, it is needed that new 
regulators for glucose metabolism have to develop to treat diabetes.  
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CHAPTER 1 
The role of SIK3 on hepatic gluconeogenesis 
 
1-1. Introduction 
 
Salt-inducible kinase (SIK) is a member of AMPK-related kinase family, and the 
SIK-subfamily is composed of three isoforms (1). SIK1 was isolated from the adrenals 
of rats fed with a high Na+ or K+ diet (2). SIK2 was identified by its sequence 
similarity (3). SIK3 was characterized by another group in a wide range analysis (4). 
Although multiple SIK-substrates have been identified based on information from the 
SIK phosphorylation motifs, Lx(R/K)(S/T)xpSxxxL (pS:phospho-Ser) (5), only two 
types of substrates, CRTC (a coactivator for the cAMP response element (CRE)-binding 
protein (CREB)) and class IIa histone deacetylase (HDAC) (6), have been confirmed by 
independent research groups. Phosphorylation of these two substrates by SIKs results in 
a loss of their transcriptional regulatory activities by inducing nuclear export (5,7). The 
other important aspect of SIK is as a feedback regulator in cAMP-activated protein 
kinase (PKA) signaling (8). When PKA activates CREB by phosphorylation, it also 
counters SIK actions by phosphorylating SIK’s C-terminal regulatory domain, which in 
turn promotes the dephosphorylation rate of CRTC, enhances nuclear accumulation of 
this coactivator, and increases CREB-dependent gene expression (5,7,9). Conversely, 
when PKA activity wanes, the reactivated SIK terminates CREB activity by inactivating 
CRTC (5,9). This is also the case for class IIa-HDAC (6). PKA-dependent inactivation 
SIK facilitates the activation of class IIa-HDAC. Because class IIa-HDAC is the major 
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suppressor of myocyte enhancer factor 2 (MEF2) (10), the MEF2-dependent 
transcription is suppressed by PKA and reactivated by SIK(6). The first physiological 
relevance of SIKs in vivo was found in the mouse liver as a suppression of 
gluconeogeneic programs (11). CREB is one of the key transcription factors that 
upregulate gluconeogenic gene expression (12) by binding to their gene promoters, such 
as phosphoenolpyruvate carboxykinase (Pepck), glucose-6-phosphatase catalytic 
subunit (G6pc), and peroxisome proliferator-activated receptor gamma coactivator 1α 
(Pgc1a: formal gene name was Ppargc1a). The knockdown of SIK1 protein in the 
mouse liver by RNAi-adenovirus vectors results in an increase in blood glucose levels, 
which is accompanied by the dephospho-form of CRTC2 and enhanced levels of 
gluconenogenic gene expression (11). However, the effects of SIK1-knockout (KO) on 
glucose metabolism have not been elucidated (13). SIK2 also may play an important 
role in glucose metabolism (3,14-17).  
Previous reports have shown that SIKs are related to glucose and lipid metabolism. 
However, it has not been elucidated whether SIK3 has a role on glucose metabolism or 
not. In this chapter, the involvement of SIK3 in glucose metabolism is demonstrated by 
using SIK3-KO mice and their hepatocytes. 
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1-2. Results 
 
Characterization of SIK3-KO mice 
The body weight of SIK3-KO mice was obviously less than that of the wild type mice. 
(Fig.1-1A). 1-year-old mice showed that the lean phenotype of SIK3-KO mice was 
attributed to the liver and adipose tissues, especially mesenteric and perirenal fat 
(Fig.1-1B). Small but substantial amounts of gonadal and subcutaneous fat and brown 
adipose tissue were observed in SIK3-KOmice. The low levels of liver TG in Sik3-/- 
mice might have prevented the development of fatty liver (Fig.1-1C), while total 
cholesterol levels were low in the serum of SIK3-KO mice. 
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A                B 
 
C 
 
Fig.1-1. SIK3-KO mice are lean and hypolipidemic.  
(A) The body weight of male mice (n = 6) was monitored. All data points show 
p,0.001. (B) One-year-old male mice (n = 5) were sacrificed (scale: 1 mm). (C) 
Cholesterol (Chol) and triglycerides (TG) in the liver and serum were measured (n = 5). 
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Next, blood glucose levels were examined. In the fed condition, the SIK3-KO mice 
had slightly lower blood glucose levels than the wild-type mice, and the levels quickly 
decreased after fasting (Fig.1-2A). After a 4-h fast, the SIK3-KO mice had significantly 
lower serum insulin and leptin levels than the wild-type mice (Fig. 1-2B), while no 
obvious differences were observed in free FA or ketone body (-hydroxybutyrate) 
levels. 
 
A B 
   
Fig.1-2. SIK3-KO mice are hypoglycemic.  
(A) Mice (n = 5) were fasted and their blood glucose levels were monitored at the 
indicated time points. All data points show p,0.001. (B) After 4-h fasting, the serum 
levels of insulin, leptin, free fatty acid (FFA), and ß-hydroxybutyrate were measured.  
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SIK3-KO mice exhibited enhanced glucose tolerance (GTT) (Fig.1-3A). When 
SIK3-KO mice were treated with insulin (ITT), their blood glucose levels decreased like 
those of the wild-type mice (Fig.1-3B). Once the SIK3-KO mice were supplied 
exogenously with an energy source, such as lactate (lactate tolerance test), they were 
able to produce glucose efficiently (Fig.1-3C), suggesting that the hypoglycemia of 
SIK3-KO mice may be due to a lack of energy storage followed by an enhanced insulin 
response.  
A                  B               C 
 
Fig.1-3. SIK3-KO mice are lean, hypolipidemic, and hypoglycemic.  
 (A) After 4-h fasting, glucose (1.5 g/kg) was intraperitoneally injected (GTT, glucose 
tolerance test) and blood glucose levels were monitored (n = 5). (B) 
(C) After 24-h fasting, lactate (1.5 g/kg) was injected intraperitoneally (LTT, lactate 
tolerance test; n = 5). 
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The gene expression profile of the liver (Fig.1-4A) indicated that the pathway from 
glycolysis to FA synthesis was down-regulated in Sik3-/- mice, while the glyconeogenic 
pathway was up-regulated. Sik3-/- mice expressed high levels of Fgf21 mRNA, 
suggesting an adaptive response to starvation; however, its promoting pathway, i.e., the 
peroxisome proliferator-activated receptor alpha (PPAR) pathway, was 
down-regulated. Lack of FA storage and the uncoupling of FGF21 from the PPAR 
pathway in Sik3-/- mice may result in the failure to induce -oxidation followed by 
ketogenesis (18). 
Next, the state of signaling molecules was examined. The high level of 
PGC-1protein in the liver of Sik3-/- mice was accompanied by the dephosphorylation 
of CRTC2 (Fig.1-4B) despite there being no significant difference in the status of CREB. 
Interestingly, the level of another CRTC2 kinase, AMPK (11), and of its activated 
phosphorylated form (pThr172) were also high in the livers of Sik3-/- mice. 
Immunohistochemical analyses revealed the enhanced accumulation of CRTC2 in the 
nuclei of Sik3-/- mice hepatocytes (Fig.1-4C). In addition, HDAC5, another SIK/AMPK 
substrate (19,20), also accumulated in the nuclei of liver cells in Sik3-/- mice, suggesting 
that AMPK is unable to compensate for the deficiency of SIK3 in hepatocytes. 
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Fig.1-4. Gene expression profile in the liver.  
(A) One-year-old male mice (n = 5) were fasted for 4 h, and the liver mRNA levels 
were measured using quantitative polymerase chain reaction (qPCR). Red and blue 
indicate the up- and down-regulated genes in Sik32/2 mice, respectively. +, fold 
increase; -, fold decrease. The threshold is set at p=0.1. The values marked with an 
asterisk (*) were obtained using PCR-array kits (n = 3). The abbreviations for the genes 
and the PCR primers used are listed in Table S2. Mit, mitochondria; TCA, tricarboxylic 
acid cycle. (B) Intracellular signaling molecules and their activation status in the liver 
were examined by western blot analysis. (C) Immunohistochemical analysis of SIK3 
substrates (CRTC2 and HDAC5) in the liver. 
13 
 
Gluconeogenic program is constitutively up-regulated in SIK3-KO Mice. 
In cultured cell systems, SIK1-3 regulates energy metabolism by apparently sharing the 
same transcriptional modulators, CRTCs (21), and ClassIIa-HDACs (22). In vivo, 
however, only SIK3-KO mice had dramatic phenotypes for energy metabolism. To 
confirm the indispensability of SIK3 in glucose metabolism in vivo, all SIKs KO mice, 
with the same genetic background (C57BL/6J), were subjected to a glucose challenge 
after 4 h of starvation (Fig. 1-5A). Although the blood glucose levels in both the WT 
and SIK3-KO mice were significantly elevated in response to the glucose treatment, the 
maximum level was significantly lower in the SIK3-KO than WT mice. However, no 
significant difference in glucose clearance between the SIK1-KO or SIK2-KO mice and 
their WT mice was observed. Next, the gluconeogenic potency in these mice was tested 
by performing a lactate (a source of gluconeogenesis) challenge under a fed condition in 
which the gluconeogenic programs had not been run in the WT liver due to insulin 
actions. The blood glucose levels in the SIK3-KO mice were quickly increased to the 
levels of the WT mice after lactate treatment, while there was no significant response in 
the glucose level to lactate in WT, SIK1-KO, or SIK2-KO mice 
(Fig. 1-5B), suggesting a constitutively activated gluconeogenic ability in the SIK3-KO 
mice.  
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Fig.1-5. Glucose metabolism in SIK1-3 KO mice. 
(A) WT and SIK1-3 KO mice (8-week-old females n = 6) were starved for 4 h (4 h after 
lights were on) and subjected to a glucose tolerance test (1.5 g/kg); the blood glucose 
level was measured. Means and SD were indicated. **, p < 0.01 compare to 0 time. (B) 
A lactate tolerance test (1.5 g/kg) was performed under the fed condition (just after the 
light was turned on). 
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Gluconenogenic programs in SIK3-KO hepatocytes 
Although the gluconeogenic gene expression has been upregulated in SIK3-KO mouse 
liver not in SIK1-KO and SIK2-KO mouse liver, the systemic effects, e.g., 
hypoglycemia, made it difficult to discuss the cell autonomous actions in the SIK3-KO 
mouse liver. To eliminate systemic effects, primary hepatocytes from SIK3-KO mice 
were prepared. 
Gene expression analyses (Fig.1-6A, genes related to gluconenogenesis: Pgc1a, Pepck, 
and G6pc) suggested that SIK3-KO hepatocytes possessed a high gluconeogenic 
potency even in unstimulated cells with almost fully enhanced gluconeogenic gene 
expression levels. Briefly, starvation (glucose-/glutamate-free) did not alter 
gluconeogenic gene expression levels in both WT and SIK3-KO mice hepatocytes. The 
stimulation of WT hepatocytes with Fsk upregulated the levels of gluconenogenic gene 
expression up to (Pgc1a and Pepck) or beyond (G6pc) those increased levels in the 
SIK3-KO hepatocytes. Western blot analyses (Fig.1-6B) detected a 
constitutively-dephosphorylated CRTC2 in the SIK3-KO hepatocytes. 
Curiously, Fsk-induced phosphorylation of CREB was not observed in the SIK3-KO 
hepatocytes. AMPK had already been phosphorylated in unstimulated SIK3-KO 
hepatocytes, suggesting an energy-depleted environment in SIK3-KO hepatocytes; 
however, the starved condition might not the major factors for the enhanced 
gluconeogenic programs in SIK3-KO mice hepatocytes. 
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A 
 
B 
 
Fig.1-6. Enhanced gluconenogenic programs in SIK3-KO hepatocytes. 
(A) The hepatocytes were pre-incubated with a low serum (1%) medium for 12 h and  
incubated in a serum-free medium, a starvation medium alone, or supplemented with 20 
μM Fsk for 3 h. Total RNA was extracted for qPCR. (n = 3). The same treatment was 
used for western blot analyses (B). 
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To confirm the glucose production from SIK3-KO hepatocytes, glucose production 
was induced by lactate, Fsk and dexamethasone. As shown in Fig.1-7, the SIK3-KO 
hepatocytes produced glucose more quickly than the WT hepatocytes (at 2 h post-Fsk 
treatment), despite a lower maximum glucose production (at 8 h).  
 
 
 
Fig.1-7. Enhanced glucose production in SIK3-KO hepatocytes. 
 Hepatocytes were prepared from 8-week-old female mice (n=3 or 4) and cultured in a 
low serum (1%) medium for 12 h. Then cells were pretreated with a starvation medium 
(serum- and glucose-/glutamate-free) for 1 h. Glucose production was induced by 10 
mM lactate, 20 μM Fsk, and 0.1 μM dexamethasone. Means and SD were indicated. *, p 
< 0.05; **, p < 0.01.  
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Identification of SIK3 signaling inhibitor 
To precisely characterize the SIK3 actions in defined culture systems, the mouse 
hepatoma AML-12 cells was used. Despite a successful knockdown of SIK1 and SIK2 
protein in AML-12 cells, SIK3 protein was hardly eliminated. Moreover, an in vitro 
screening for SIK3 inhibitors from our chemical library (~2,500 compounds) resulted in 
only an identification of non-specific inhibitors, such as the flavonoid fisetin (23). To 
identify an inhibitor of the SIK3-specific signal, reporter-based screening using 
transcription regulators (class IIa-HDAC and CRTC2) that were suppressed by SIKs 
was used. Fig.1-6A indicates the principles of the reporter system. Because SIK3 
inhibited the suppressive action of class IIa-HDAC on the transcription factor MEF2, 
the firefly luciferase (fLuc) activity under the regulation of the GAL4 fusion MEF2 is 
upregulated by SIK3 and downregulated by the SIK3 inhibitory compounds, such as the 
non-specific kinase inhibitor staurosprine (STS) (21) (Fig.1-8B). CRTC2 is also 
inhibited by SIK3; thus, the Renilla by LEXA-fusion CRTC2 was suppressed by SIK3, 
and STS upregulated the LEXA-rLuc activity. The combination of these two reporters 
in the same cells produced approximately 25 times the S/N ratio, when SIK3 was 
inhibited by STS. Using these reporters and HEK293 cells, pterosin B, an ingredient in 
Pteridium aquilinum, was identified as a candidate for SIK3 signaling inhibition 
(Fig.1-8C). The action of pterosin B on MEF2 and CRTC2 were also confirmed in 
separately assayed fLuc reporter systems in the AML-12 cells (Fig.1-8D). The 
structural-activity relationship assay suggested that only pterosin S failed to inhibit 
SIK3 signaling (Fig.1-8E). Synthetic pterosin B (racemic) also inhibited SIK3 signaling, 
indicating that pterosin B, not non-pterosin contaminants, inhibited SIK3 signaling. 
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Fig.1-8. Pterosin B inhibits SIK3 signaling. 
(A) A principle of reporter-based chemical screening. (B) A model experiment of reporter 
assays using the non-specific kinase inhibitor staurosporine (STS, 10 nM). The fold difference 
in un-normalized luciferase activities between SIK3-overexpression alone and SIK3 + STS was 
indicated (n = 3). (C) The result of a representative plate containing pterosin B was indicated. 
Fsk (20 μM) and Okadaic acid (OA, 1 μM) are positive controls for SIK3 inhibition. 
Compounds were classified into kinase inhibitors, and uncharacterized compounds, and natural 
compounds were treated for 36 h at 10 μM, 10 μg/mL, and 50 μg/mL, respectively. Some 
compounds showed high ratios due to errors, such as cell toxicity. (D) MEF2 and CRTC2 
activity were measured in the same GAL4-based firefly luciferase system in the AML-12 cells. 
(E) Structural activity relationship of pterosin B and its derivatives. HEK293 cells were 
transformed with the MEF2 or CRTC2 reporter together with the SIK3 expression vector. 
Compounds (300 μM) were treated for 36 h. n = 2-3. 
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To visually evaluate the inhibitory actions of pterosin B on SIK3 signaling, green 
fluoresce protein (GFP)-fusion HDAC5 (a class IIa-HDAC) and CRTC2 were 
expressed together with SIK3. Both HDAC5 (Fig.1-9A) and CRTC2 (Fig.1-9B) were 
localized in the cytoplasm in the SIK3-overexpressing cells, and pterosin B inhibited 
this cytoplasmic localization, suggesting that pterosin B was able to inhibit downstream 
cascades of SIK3 signaling. 
 
 
Fig.1-9. Pterosin B inhibits cytoplasmic localization of HDAC5 and CRTC2. 
GFP-fusion HDAC5 (A) or CRTC2 (B) were overexpressed in HEK293 cells with or without 
SIK3 overexpression. Pterosin B (300 μM) was treated for 36 h. The localization of GFP signals 
in 100 positive cells was classified into three categories, cytoplasmic (C), nucleus (N), and both 
(C/N) and showed as %. 
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 To examine whether pterosin B inhibits SIK3 signaling and mimics the glucose 
metabolism observed in SIK3-KO hepatocytes, both WT and SIK3-KO hepatocytes 
were treated with pterosin B, and glucose production was monitored (Fig.1-10A). 
Pterosin B quickly increased the medium glucose levels in WT hepatocytes, which was 
accompanied by enhanced expression of gluconeogenic genes (Fig.1-10B). However, no 
further enhancement of glucose production or gluconeogenic gene expression by 
pterosin B was observed in the SIK3-KO hepatocytes, suggesting that pterosin 
B-induced gluconeogenesis may be mediated by SIK3. Prolonged treatment with 
pterosin B was found to decrease glucose levels in the WT hepatocyte medium, and 
G6pc gene expression in SIK3-KO hepatocytes was downregulated by pterosin B. 
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Fig.1-10. Pterosin B upregulates glucose production and gluconeogenic gene 
expression in WT hepatocytes, but not in SIK3-KO hepatocytes. 
(A) Hepatocytes were prepared from 12-week-old female WT (left panel) or SIK3-KO 
(right panel) mice (n = 3) and cultured in a low serum (1%) medium for 12 h. The cells 
were then pretreated with a starvation medium (serum and glucose/glutamate free) for 1 
h. Glucose production was induced by 10 mM lactate and 0.1 μM dexamethasone in the 
presence or absence of pterosin B (300 μM). The means and SD are shown. **, p < 0.01. 
(B) The hepatocytes were pre-incubated with a low serum (1%) medium for 12 h and 
incubated in a serum-free medium, a starvation medium alone, or supplemented with 
pterosin B (300 μM). Total RNA was extracted for qPCR. (n = 3). 
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1-3. Discussion 
 
SIK3-KO mice display a lean phenotype and excessive hypoglycemia. Although, a 
response to insulin and lactate-induced gluconeogenesis in SIK3-KO mice appeared to 
be normal under fasting condition, gluconeogenic gene expression was extremely higher 
in the SIK3-KO liver than in WT mice. The lean phenotype (small amount of energy 
storage) can make it difficult to determine whether enhanced gluconeogenic programs 
in the SIK3-KO mice liver were the results of a cell-autonomous action or systemic 
effects. Therefore, a role of SIK3 on glucose metabolism in isolated hepatocytes from 
SIK3-KO mice was examined. SIK3-KO primary hepatocytes produced glucose more 
quickly after treatment with the cAMP agonist forskolin than the WT hepatocytes, 
which was accompanied by enhanced gluconeogenic gene expression and CRTC2 
dephosphorylation. Pterosin B inhibited SIK3-dependent cytoplasmic localization, 
suggesting that pterosin B was able to inhibit downstream cascades of SIK3 signaling. 
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CHAPTER2 
Pterosin B regulates hepatic gluconeogenesis  
via a SIK3-dependent mechanism.  
 
2-1. Introduction 
 
In the chapter2, the relation between pterosin B and SIK3 signal in respect to hepatic 
gluconeogenesis is described.  
 
2-2. Results 
 
Pterosin B represses SIK3 signaling via the C-terminal regulatory region 
To test the specificity of pterosin B toward SIKs, SIK1-3 was examined in the same 
reporter assay in the HEK293 cells (Fig.2-1A). The upregulation of MEF2 and 
downregulation of CRTC2 activities by SIK1 or SIK2 were not affected by pterosin B, 
indicating that pterosin B specifically inhibited SIK3 signaling. On the other hand, 
pterosin B did not inhibit SIK3 kinase activity up to 1 mM, while the strong pan-SIK 
inhibitor HG9-91-01 (1) completely inhibited SIK3 kinase activity even at 1 μM (Fig. 
2-1B). Because SIK3 was activated by phosphorylation at Thr163 by the upstream 
kinase LKB1 (2), the phosphorylation status at this site on the overexpressed SIK3 in 
HEK293 cells was examined (Fig.2-1C). Western blot analyses with 
anti-phospho-Thr163 revealed that pterosin B did not alter the phosphorylation level at 
this site. The alternative candidate sites for inhibition of the SIK3 actions were in the 
29 
 
C-terminal regulatory domains of Thr411 and Ser493 (Fig.2-1D) (3). The 
phosphorylation of these sites suppressed SIK3’s CRTC-inhibitory activity. To confirm 
the importance of the C-terminal domain, reporter assays with various SIK3 mutants 
were used. The truncation of the C-terminal domain (kinase domain only) converted 
SIK3 into a pterosin B-resistant mutant (Fig.2-1D). The actions of double mutant SIK3 
(DA: T411A and S493A) were also not affected by pterosin B (Fig.2-1E), despite a 
small difference between the MEF2 and CRTC2 systems (Thr411 may be more critical 
for CRTC2 regulation than Ser493). Indeed, the phosphorylation levels at Thr411 and 
Ser493 were upregulated in mouse hepatoma AML-12 cells treated with pterosin B, 
which was also found in Fsk-treated cells (Fig.2-2A). Ser493 may be phosphorylated by 
PKA (4), and overexpression of PKA in HEK293 cells mimicked the pterosin actions 
on MEF2 and CRTC2 (Fig.2-2B). However, the PKA inhibitor H89 did not block 
pterosin B-dependent suppression of SIK3 signaling (Fig.2-2C). Although Thr411 is 
probably phosphorylated by PKA or CaMKs, the overexpression of CaMK I/II or the 
treatment with the CaMK inhibitor KN62 disproved the involvement of these kinases in 
the pterosin B-dependent suppression of SIK3 signaling (Figs.2-2B and 2-2C). In 
addition, the cAMP-responsible luciferase system showed that pterosin B reduced the 
intracellular cAMP levels induced by Fsk (Fig.2-2D). These results suggested that 
unknown kinases, rather than PKA or CaMK I/II, might phosphorylate SIK3 in Thr411 
and Ser491, which inhibited SIK3 signaling. 
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Fig.2-1. Pterosin B represses SIK3 signaling via the C-terminal regulatory region. 
(A) HEK293 cells were transformed with the MEF2 or CRTC2 reporter together with the 
SIK1-3 expression vectors and treated with pterosin B (300 μM) for 36 h. The fold differences 
in the reporter activities by the pterosin B treatment were indicated (n = 3, Means and SD.). (B) 
In vitro kinase assay. The GST-SIK3 enzyme was expressed in HEK293 cells, purified with a 
glutathione resin and incubated with compounds, the coumarin-labeled CRTC2 peptide, and 1 
mM ATP for 1 h. The phosphorylated and non-phosphorylated peptides were separated by 
electrophoresis. (C) HEK293 cells overexpressing GST-SIK3 (WT and T163A mutant) were 
treated with pterosin B (300 μM) for 36 h, and then the GST-SIK3 were purified and subjected 
to the in vitro kinase assay and western blot analysis. (D) Upper diagram shows phosphorylation 
sites in SIK3. HEK293 cells were transformed with reporters together with the SIK3 expression 
vectors as (A). (E) The same experiments with SIK3-phoshorylation site mutants were 
performed. 
31 
 
 
Fig.2-2. PKA or CaMKs is not responsible kinase for the pterosin B-mediated suppression 
of SIK3 signaling. 
(A) AML-12 cells were transfected with SIK3 (WT and DA mutant) adenoviruses and were 
treated with pterosin B (300 μM) or Fsk (20 μM). Three hours later, SIK3 protein was purified 
with anti-SIK3 antibodies and subjected to western blot analyses. (B) HEK293 cells were 
transformed with the MEF2 or CRTC2 reporter together with the SIK3 and PKA or CaMK I/II 
expression vector. Luciferase activities were measured after 36 h. n=3. (C) Effects of various 
inhibitors on pterosin B-mediated suppression of SIK3-dependent MEF2C activity. H89 (20 μM, 
PKA inhibitor), KN62 (10 μM, CaMK inhibitor), Rapamycin (1μM, PI3K/Akt/mTOR signal 
inhibitor), LY364947 (10 μM, TGF-β receptor inhibitor), BAY 11-7082 (10 μM, IKK inhibitor), 
SB-203580 (10 μM, p38 inhibitor), SP600125 (10 μM, JNK inhibitor), PD98059 (10 μM, MEK 
inhibitor), and STO609 (30 μM, CaMKK inhibitor) were used. (D) AML-12 cells that had been 
transformed with the cAMP sensor plasmid GloSensor™ were treated with Fsk (20 μM) 
together with or without pterosin B (300 μM). The cellular cAMP level was monitored as 
luciferase activities. 
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Pterosin B-resistant SIK3 decreases glucose production and CRTC2 
dephosphorylation in AML-12 cells  
To specifically examine the signaling in pterosin B-induced gluconeogenesis and the 
relevance of the importance of the C-terminal domain of SIK3, glucose production in 
AML-12 cells after pterosin B treatment was examined. Pterosin B increased glucose 
production as quickly as Fsk, while HG9-91-01 increased it gradually (Fig.2-3A). At 8 
h post-stimulation, however, the glucose level in pterosin B-treated cells was returned to 
the basal level. Because the higher potential of pterosin B on glucose production than 
HG9-91-01 suggested the presence of SIK-independent pathways in pterosin B actions, 
pterosin B-induced glucose production in the AML-12 cells that had been transfected 
with SIK3-adenoviruses was examined. Overexpression of SIK3 lowered the pterosin 
B-induced glucose production, which was more evident in cells that expressed pterosin 
B-resistant SIK3 DA mutant than in pterosin B-sensitive SIK3 (WT) (Fig.2-3B). Next, 
The levels of gluconeogenic gene expression in the pterosin B-treated AML-12 cells 
was examined. Cells were pretreated with serum-free medium for 1 h and then, 
incubated with pterosin B or other compounds in the absence of glucose for 3 h. 
Pterosin B upregulated Pgc1a, Pepeck, and G6pc mRNA levels with different efficacies, 
which was also represented by Fsk and HG9-91-01 with different target specificities  
(Fig.2-3C). Again, it was examined whether SIK3 overexpression was able to suppress 
pterosin B-induced gluconeogenic gene expressions. All expressions were suppressed 
by SIK3 overexpression, and SIK3 DA was more efficient than SIK WT (Fig.2-3D). 
Then, the protein status involved in gluconeogenesis was examined. Pterosin B quickly 
induced the dephosphorylation of CRTC2 in AML-12 cells (Fig.2-3E), which was also 
observed in Fsk- and HG9-91-01-treated cells. CREB phosphorylation at Ser133 was 
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upregulated with starvation time in the control (DMSO) cells. However, the treatment 
with pterosin B or HG9-91-01 inhibited the CREB phosphorylation. An increase in 
AMPK phosphorylation levels at Thr172 was further upregulated in pterosin B-treated 
cells and downregulated in Fsk-treated cells. HG9-91-01 apparently showed no effect 
on the AMPK phosphorylation levels. Similarly to other assays, SIK3 overexpression 
returned the levels of pterosin B-induced dephosphorylation of CRTC2 and 
phosphorylation of CREB (Fig.2-3F), which was, again, more evidently with SIK3 DA 
than SIK3 WT. These results suggested that dephosphorylation of CRTC2 by pterosin B 
might induce gluconeogenic programs, and the inactivation of SIK3 due to enhanced 
phosphorylation of its C-terminal domain might be a mechanism of these programs. 
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Fig.2-3. Pterosin B resistant SIK3 suppresses pterosin B induced gluconeogenic 
programs. 
(A) AML-12 cells that had been incubated in 1% serum medium for 12 h were further 
pre-incubated with the starvation medium (serum- and glucose-/glutamate-free) for 1 h. Means 
and SD were indicated (n = 4). *, p < 0.05; **, p < 0.01 (compared with the control group, 
DMSO). Glucose production was induced by pterosin B (300 μM), Fsk (20 μM), or HG9-91-01 
(1 μM) in the presence of 10 mM lactate and 0.1 μM dexamethasone. (B) AML-12 cells that had 
been transfected with the SIK3 (WT and DA mutant) adenoviruses were subjected to glucose 
production assays (at 3 h). *, p< 0.05 (compared with the control pterosin B group, Vector)  
(C) Gluconeogenic mRNA were examined in the AML-12 cells. Cells that were incubated with 
a serum-free medium for 12 h and treated with compounds (same as A) in the starvation 
medium for 3 h (n = 3). (D) The pterosin B-induced gene expression was analyzed in the 
SIK3-overexpressing AML-12 cells. E. Western blot analyses of AML-12 cells that were 
treated as in C. F. The pterosin B treatment was for 3 h. MOI, multiplicity of infection. 
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Involvement of PHKG2 in pterosin B-mediated inactivation of SIK3 
Finally, the molecules mediating pterosin B action on SIK3 were identified, which 
could be a kinase or a phosphatase. Some candidates were overexpressed in the MEF2 
and CRTC2 reporter systems in HEK293 cells, and SIK3-dependent activation and 
repression were evaluated in the presence or absence of pterosin B (Fig.2-4A). It has 
been reported that the phosphatases PP1, PP2A, and calcineurin (Cn) modulate CRTC2 
activity (5). However, these phosphatases modulate reporter activities of either MEF2 or 
CRTC2. Pyruvate dehydrogenase kinase (PDK) and pyruvate dehydrogenase 
phosphatase (PDP) are key regulators in mitochondria and regulate acetyl-CoA 
production by modulating pyruvate dehydrogenase (PDH) activity (6). PDH activity is 
inextricably linked with pyruvate carboxylase, producing oxaloacetic acid, which is the 
initial metabolite of gluconeogenesis. However, PDK(s) and PDP(s) did not modulate 
SIK3-dependent MEF2 or CRTC2 activities. When gluconeogenesis is activated in 
hepatocytes, glycogenolysis could also be activated. The key molecules regulating 
glycogenolysis are phosphorylases and are activated by phosphorylase kinase catalytic 
gamma 2 (PHKG2). Indeed, PHKG2, but no the muscle type PHKG1, inhibited the 
SIK3-dependent regulation of both MEF2 and CRTC2, which is accelerated by pterosin 
B (when SIK3 is inhibited, the fold change approaches 1). In addition, 3 h of treatment 
with pterosin B decreased the glycogen content in AML-12 cells in a dose-dependent 
manner (Fig.2-4B), suggesting that pterosin B stimulates glycogenolysis.  
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Fig.2-4. PHKG2 inactivates SIK3 in response to pterosin B. 
(A) A reporter assay was performed in HEK293 cells. Some kinases and phosphatases were 
overexpressed together with GAL4-MEF2 or GAL4-CRTC2 reporters (see FIGURE 2B). Bars 
indicate fold activation (MEF2) or repression (CRTC2) by SIK3 overexpression (n = 3). In 
SIK3 without transcriptional regulatory activity, the fold change (activation or repression) 
approaches 1 (no change). Pterosin B was added at 300 μM. (B) AML-12 cells that had been 
cultured for 72 h with daily medium change were incubated with various concentrations of 
pterosin B (0–300 μM) for 3 h. The glycogen concentrations were then measured (left panel). 
Intracellular accumulation of glycogen was observed after PAS staining (right panel). 
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An in vitro kinase assay of PHKG2 and SIK3 peptide corresponding to the regions of 
Thr411 and Ser493 indicates that PHKG2 can phosphorylate SIK3 (Fig.2-5A). GST 
pull-down in AML-12 cells suggests that PHKG2 binds to SIK3 in response to pterosin 
B (Fig.2-5B) in a T411- or S493-phosphorylation-independent manner (Fig.2-5C). The 
association with PHKG2 was only observed when SIK3 was used as bait (Fig.2-5D). On 
the other hand, the overexpression of PHKG2 in AML-12 cells had less of an effect on 
the SIK3 cascades downstream, probably because of the limited amount of SIK3 
protein.  
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A                        B 
 
 
C                        D 
 
Fig.2-5. PHKG2 inactivates SIK3 in response to pterosin B. 
(A) The GST-fusion PHKG2 enzyme was overexpressed in COS-7 cells and purified using 
glutathione column. Fluoro-peptides corresponding to SIK3 Thr411 and Ser493 were incubated 
with GST-PHKG2 in the presence of ATP. Phosphorylated peptides were separated by 
electrophoresis on agarose gel. (B) GST-SIK3 were overexpressed in AML-12 cells in the 
presence of Halo-tagged PHKG1/2 and pull-down by glutathione sepharose after 3 h of 
pre-treatment with pterosin B (300 μM). PHKG1/2 and phospho-SIK3 (pS) were detected by 
anti-Halo-tag antibody and anti-pS493, respectively. (C) GST-SIK3 WT and T411A/S493A 
mutant (DA) were used. (D) GST SIK1-3 were used. 
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To show the indispensable role of PHKG2 in pterosin B-mediated SIK3 inactivation, 
knockdown experiments were performed in AML-12 cells. Two different miRNA 
vectors for mouse PHKG2 decreased the protein levels and lowered the phosphorylation 
levels of SIK3 pT411 and pS493 (Fig.2-6A), in contrast to CRTC2 phosphorylation 
levels. Pterosin B-induced gluconeogenic gene expression was also suppressed by 
PHKG2 knockdown (Fig.2-6B), suggesting that PHKG2 is a new regulator of SIK3 as 
elicited by pterosin B. 
 
Fig.2-6. PHKG2 inactivates SIK3 in response to pterosin B. 
(A) PHKG2 protein was knocked down in AML-12 cells by transformation with miRNA 
plasmid vectors. (B) The same sequences of miRNA were transferred into an adenovirus vector 
and knocked down PHKG2 protein in AML-12 cells to monitor pterosin B-induced 
gluconeogenic gene expression (300 μM, 2 h). n = 3, **, p < 0.01 (compared with the control 
group, LacZ - pterosin B).  
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2-3. Discussion 
 
 In this chapter, it has been demonstrated that pterosin B suppressed SIK3 downstream 
cascades by up-regulating the phosphorylation levels in the SIK3 C-terminal regulatory 
domain. When pterosin B promoted glucose production by up-regulating gluconeogenic 
gene expression in AML-12 cells, it decreased the glycogen content and stimulated an 
association between PHKG2 and SIK3. PHKG2 phosphorylated the peptides with 
sequences of the C-terminal domain of SIK3.  
PHKG2 belongs to the CaMK family (7) and shares phosphorylation motifs with 
CaMKs and PKA (8). A major role of PHKG2 is the initiation of glycogen breakdown 
in response to glucagon-cAMP-PKA or Ca2+ signaling by phosphorylating 
phosphorylase (9). Mutations in the PHKG2 gene cause type IXc glycogen storage 
disease (GSD: liver glycogenosis), which is characterized by hypoglycemia, lactic 
acidosis, and cirrhosis (10). Although glucagon response was found in type IX GSD 
patients (11), some patients with PHKG2 gene mutations were reported to not or weakly 
respond to glucagon (12). In addition, Type Ia GSD, G6Pc deficiency (13), and PEPCK 
deficiency (liver isoform PCK1) (14)commonly cause lactic acidosis, suggesting the 
dysregulation of gluconeogenesis in PHKG2-mutated patients. A decrease in the 
glycogen content in pterosin B-treated AML-12 cells, capability of SIK3 
phosphorylation by PHKG2 in vitro, specific association of PHKG2 with SIK3, and 
weakened action of pterosin B in PHKG2 knocked-down AML-12 suggest that pterosin 
B inactivates SIK3 via the activation of PHKG2. These results suggest that pterosin B 
suppress SIK3 via PHKG2. 
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Fig.2-7. Hypothetical model of SIK3 signaling. 
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CHAPTER 3 
Pterosin B regulates hepatic gluconeogenesis  
via a SIK3-independent mechanism.  
 
3-1. Introduction 
 Hsu et al., (1) had reported that pterosin A (a derivative of pterosin B) lowered blood 
glucose levels and hepatic Pck1 expression in mice, coupled with AMPK activation. In 
addition, our study in chapter 3 also found that the magnitude of pterosin B-induced 
G6pc gene expression was much lower than that induced by forskolin (a cAMP-agonist) 
in mouse hepatoma cell line, AML-12, suggesting that pterosin B (probably pterosin A 
as well) affects gluconeogenic gene expression at multiple sites and not only at the 
SIK3-CRTC2 cascade. 
The retinoic acid receptor-related orphan receptor (ROR) family of transcription 
factors is composed of three isoforms (α, β, and γ), which play important roles in a 
variety of physiological events, including glucose and lipid metabolism, development of 
immune- and neural-systems, and circadian rhythms (2,3). In this family, RORα has 
been found to be regulated by cAMP signaling (4). Studies using knockout models and 
specific ligands of RORα suggested a participation of this transcription factor in the 
regulation of gluconeogenesis (5,6). Steroid receptor coactivator 2 (SRC2) activates 
RORα on the G6pc promoter, and the deficiency in either RORα or SRC2 shares 
phenotypes (hypoglycemia and excess glycogen storage) with G6Pc deficiency, which 
is classified as glycogen storage disease type 1a (Von Gierke's Disease) (5,7). 
In this chapter, a new regulation site of pterosin B via a SIK3 -independent mechanism 
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is described. 
 
3-2. Results 
 
Suppress forskolin-dependent hepatic glucose production 
Since pterosin A, a derivative of pterosin B, has anti-diabetic effects in 
streptozotocin-treated mice and db/db mice (1), db/db mice were fed with a diet 
containing pterosin B. Like pterosin A, an 1-month treatment with pterosin B also 
lowered blood glucose levels and enhanced insulin responses in these mice (Fig.3-1B). 
Although pterosin B has the potential to promote gluconeogenic gene expression via 
CRTC2 activation, the glucose production induced by it lasted for only several hours in 
the AML-12 cel. Thus, the glucose production in mouse hepatocytes stimulated with 
pterosin B, forskolin, and their combination was re-evaluated. Although pterosin B and 
forskolin synergistically upregulated glucose production at 1 h post stimulation 
(Fig.3-1C), pterosin B acted as a suppressor of forskolin-dependent glucose production 
in later phases (4 h). 
Synergistic or additive induction by pterosin B and forskolin was observed in 
Ppargc1a and Pck1 mRNA expression (Fig.3-1D). Although G6pc expression was 
upregulated by pterosin B, the magnitude was much less than that induced by forskolin. 
Moreover, forskolin-induced G6pc gene expression was strongly suppressed by 
co-treatment with pterosin B. These results suggest that pterosin B alone had the 
potential to promote gluconeogenic programs; however, in the cAMP cascades, it might 
act as a suppressor of gluconeogenesis by inhibiting G6pc expression. 
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Fig.3-1. Pterosin B lowers blood glucose levels in db/db mice 
(A) Pterosin B structure. (B) db/db mice (10-week-old males, n = 6) that had been fed with diets 
(chow ± pterosin B, 0.1%: approximately 100 mg/kg/day) for 1 month were subjected to 
glucose tolerance test (GTT: 1.5 g/kg glucose) or insulin (ITT: 36 μg/kg insulin) tolerance test. 
Means and s.d. are shown. *: p < 0.05, **: p < 0.01. (C) Mouse hepatocytes (C57BL/6J) were 
incubated with 1 mM pyruvate and 10 mM lactate, and glucose production was stimulated with 
pterosin B (300 µM), forskolin (10 µM), or their combination. The culture media were collected 
to measure glucose at 1, 2, 4, and 8 h, and “stimulated glucose-production” was calculated by 
subtraction of glucose levels in control groups (DMSO) from those in individual stimulant 
groups (n = 4). (D) Mouse hepatocytes (n = 3) had been pre-incubated in the DMEM medium 
supplemented with 2.5 mM glucose (pyruvate and glutamine free) for 1 h and then treated with 
pterosin B (300 µM) or forskolin (10 µM) for 2 h. The mRNA expressions of gluconeogenic 
genes were measured by quantitative PCR. The level of each mRNA was normalized by that of 
Tbp (TATA-box binding protein). 
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Pterosin B inhibits RORα-SRC2 interaction 
Results from previous reports suggest that the loss of the Src2 gene in mouse 
hepatocytes results in a lowered G6pc expression without affecting Pck1 expression (5). 
Because SRC2 is recruited to RORα on the G6pc gene promoter, whether pterosin B 
targeted RORα–SRC2 was tested. Pterosin B alone upregulated G6pc promoter activity 
and downregulated forskolin-dependent G6pc promoter activity in AML-12 cells (Fig. 
3-2A). Once the ROR-response element was disrupted, pterosin B-dependent 
suppression of the forskolin-induced G6pc promoter activity was not observed. 
Curiously, although RORα overexpression resulted in a significant enhancement of the 
wild type G6pc promoter activity (Fig.3-2B), pterosin B failed to modulate this activity. 
On the other hand, pterosin B suppressed SRC2-induced G6pc promoter activity, 
suggesting that SRC2 might be the major target of pterosin B, and RORα might be 
transmitting the SRC2 actions to the G6pc promoter together with activities of pterosin 
B-insensitive unknown factors. 
To examine whether pterosin B interrupted the RORα–SRC2 interaction, GAL4-fusion 
RORα expression constructs were prepared (Fig.3-3A). When full length RORα was 
used as a bait, detecting the effect of SRC2 overexpression was failed. However, the 
deletion of the DNA-binding domain from RORα highlighted the coactivator activity of 
SRC2 (left panel), which was promoted by forskolin and suppressed by pterosin B 
(right panel). Because the ROR family is composed of three isoforms, the target 
isoform for pterosin B was examined. SRC2-dependent RORα activity was suppressed 
by pterosin B (Fig.3-3B), whereas the activities of RORβ/γ were not clearly affected by 
SRC2 or pterosin B.  
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Fig.3-2. Pterosin B disrupts RORα–SRC2. 
(A) AML-12 cells transformed with the G6pc reporter (WT or mutant, ROR-element 
disrupted (MUT)) were treated with pterosin B (300 µM) and forskolin (10 µM) for 6 h. 
G6pc promoter–reporter activity (firefly luciferase) was normalized by the internal 
Renilla luciferase activity (TK-rLuc), and the control was set to 1. Means and s.d. are 
shown (n = 3). *: p < 0.05, **: p < 0.01. (B) Expression vectors (RORα and SRC2) 
were co-transformed with the wild-type G6pc promoter–reporter vector, and cells were 
then treated with pterosin B.  
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Fig.3-3. Only RORα is affected by SRC2 and pterosin B.  
(A) GAL4-fusion RORα (full length and only the ligand-binding domain (LBD)) was 
expressed as a bait in AML-12 cells. DBD: DNA-binding domain. The RORα 
transcription activities were evaluated as GAL4 (USA)-Tk-Luc activities, and the 
effects of SRC2 overexpression on these two RORα activities were examined (left). The 
RORα LBD was used to evaluate the effect of pterosin B or forskolin (right). (B) The 
effects of SRC2 overexpression and pterosin B on the transcription activities of RORα, 
β, and γ LBD were examined. 
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Pterosin B interrupts the oxidation-reduction cycle of coenzyme Q 
The disruption of Rorα in mice (sg/sg) resulted in dysregulation of energy metabolism 
(8). Recently, RORα was found to sense mitochondrial stress in hepatocytes and thereby 
regulate glycolytic gene expression (9). On the other hand, the Src2 gene deletion 
impaired mitochondrial respiration followed by a decrease in ATP production (10). To 
examine the involvement of pterosin B in mitochondrial energy metabolism, cellular 
ATP levels in AML-12 cells, maintained under a variety of medium conditions, were 
measured. When the cells were maintained in glucose-, pyruvate-, and glutamine-free 
medium, pterosin B lowered the cellular ATP levels (Fig.3-4A). Glucose enhanced 
cellular ATP levels, and this was not suppressed by pterosin B. However, once the 
glycolysis inhibitor 2-deoxyglucose was added, glucose-dependent ATP production was 
reduced by pterosin B, and it completely inhibited pyruvate-induced ATP production, 
suggesting that pterosin B might suppress ATP production in the mitochondria. 
Fig.3-4B illustrates OXPHOS and compounds that have been used in this study. The 
monitoring of the oxygen consumption rate by the flax analyzer revealed that pterosin B 
suppressed mitochondrial respiration, which was emphasized as maximum oxygen 
consumption (Fig.3-4C: the uncoupled state as a result of FCCP treatment). 
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Fig.3-4. Pterosin B impairs oxidation–reduction cycle of coenzyme Q.  
(A) AML-12 cells were pre-incubated with DMEM ((-) glucose, pyruvate, and glutamine) for 1 
h. Pterosin B (300 µM) was added to the medium, together with 2 mM glucose or 2 mM 
pyruvate ± 2 mM 2-deoxyglucose (2DG). After 30 min, the cells were lysed to measure ATP 
levels. Means and s.d. are shown (n = 4). **: p < 0.01. (B) Reagents used to analyze 
mitochondrial oxidative phosphorylation are depicted. Rotenone, malonic acid, antimycin A, 
and oligomycin are inhibitors for complex I, II, III, and V, respectively. FCCP is an uncoupler 
that transfers protons from the membrane space to the inner matrix. Ascorbic acid and 
tetramethyl-p-phenylene-diamine (TMPD) reduces cytochrome C (Cytc). Q indicates coenzyme 
Q. (C) AML-12 cells (n = 3) incubated in DMEM medium supplemented with 2 mM pyruvate 
and 1 mM glutamine (glucose free) were subjected to oxygen consumption measurements using 
the flax analyzer. Pterosin B (300 µM) or DMSO was added at indicated time points. Oxygen 
consumption rate (OCR) for six rounds of measurement was set to 100%. Means and s.d. are 
shown. 
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To predict the target of pterosin B in OXPHOS, the levels of ATP and NADH (cellular 
energy representatives) in the presence of a variety of respiratory toxins were compared 
(Fig3-5A). As described in Fig3-4A, a high dose of pterosin B decreased cellular ATP 
levels, which was also observed in the cells treated with other toxins (Fig.3-5B). 
Pterosin B lowered cellular NAD(P)H levels, whereas, other toxins did not (Fig.3-5C). 
Interestingly, mitochondrial NADH levels were upregulated by pterosin B or antimycin 
A (a complex III inhibitor) (Fig.3-5D). 
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Fig.3-5. Measurement of ATP and NADH 
(A) The principle of measurement of ATP and NADH. MTT is reduced by NADH in the 
mitochondria and converted into colored formazan, whereas water-soluble tetrazolium salt 
(WST) is reduced in the medium via cytosolic NAD(P)H-dependent reduction of the proton 
transducer 5-methylphenazinium methylsulfate (PMS). (B) AML-12 cells (n = 4) that had been 
pre-incubated with DMEM supplemented with 2.5 mM glucose, 1 mM pyruvate, and 1 mM 
glutamine were treated with indicated doses of pterosin B and respiratory toxins (rotenone, 
antimycin A, and oligomycin) for 30 min. Cellular ATP (B) and NAD(P)H (C) were measured 
by using the luciferase (Luc)-based ATP assay kit and WST-8, respectively. Mitochondrial 
NADH (D) was measured using the MMT assay kit. Means and s.d. are shown. *: p < 0.05, 
**: p < 0.01.  
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 Next, ATP production in mitochondria isolated from AML-12 cells was measured 
(Fig. 3-6). It was defined that oligomycin-inhibited ATP production is the result of 
OXPHOS. When ATP was produced from carried-over substrate ((-) in Fig.3-6A), 
pterosin B significantly inhibited ATP production, which was slightly enhanced by the 
addition of pyruvate plus malate (complex I substrate). While, the pterosin B-dependent 
suppression of ATP production was weakened by the addition of succinate (complex II 
substrate). When rotenone (complex I inhibitor) was added to evaluate complex 
II-dependent electron transfer, pterosin B again inhibited the succinate-dependent ATP 
production only by 50% (Fig.3-6B), suggesting that complex I pathways might be the 
main target of pterosin B. On the other hand, once cytochrome c (downstream of 
complex III) was chemically reduced by adding ascorbic acid plus TMPD in the 
absence of complex I and II activities, the ATP production was not affected by pterosin 
B (Fig.3-6C), suggesting that the pterosin B target might be located upstream of 
complex III and downstream of complex I and II. 
 
 
 
 
 
 
 
 
 
 
55 
 
A                    B                   C                        
 
Fig.3-6. Pterosin B inhibits ATP production in mitochondria. 
(A) ATP production in isolated mitochondria was initiated by addition of ADP. (-) indicates ATP 
production from endogenous (carried over) substrates in isolated mitochondria. 100 μM 
pyruvate plus 100 μM malate were added as complex I substrates. 100 μM succinate was added 
as the complex II substrate. (B) To evaluate complex II-dependent ATP production, 50 μM 
rotenone was added. (C) For downstream activation of complex III, complex I and II were 
inhibited by rotenone and 1 mM malonic acid, and cytochrome C was reduced by 500 μM 
ascorbic acid plus 125 μM TMPD.  
 
 
 
 
If the complex III (coenzyme Q : cytochrome c–oxidoreductase) was inhibited, the 
reduced form of coenzyme Q would be allowed to accumulate. To test whether pterosin 
B affected the oxidation–reduction cycle of coenzyme Q, coenzyme Q was extracted 
from HEK293 cells that had been treated with pterosin B or antimycin A (Fig.3-7). It 
was found that pterosin B as well as antimycin A caused the accumulation of reduced 
coenzyme Q. 
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Fig.3-7. Pterosin B impairs oxidation–reduction cycle of coenzyme Q. 
(A) Authentic coenzyme Q10 (oxidized: CoQ10 and reduced: CoQ10H2) were separated by 
HPLC (left panel). (B) The percentage of reduced coenzyme Q10 in HEK293 cells that had 
been treated with pterosin B, antimycin A (3 μM), or oligomycin (0.3 μM) for 30 min is 
indicated (right panel). 
 
 
Both pterosin B and antimycin A disrupt RORα–SRC2 signaling 
To review the actions of respiratory toxins on gluconeogenic programs, mRNA levels 
for gluconeogenic gene in AML-12 cells were measured. Forskolin-induced expressions 
of both Pparcg1 and Pck1 were inhibited by rotenone and oligomycin, but not by 
antimycin A (Fig.3-8A). However, G6pc gene expression was inhibited by all the toxins, 
suggesting the association of multiple regulatory pathways with the G6pc promoter. To 
focus only on RORα–SRC2 actions, GAL4-fusion RORα was used again. Only pterosin 
B and antimycin A suppressed the SRC2-mediated activation of RORα (Fig.3-8B). 
Immunoprecipitation followed by western blotting revealed that RORα–SRC2 
interactions were disrupted by both pterosin B and antimycin A. On the other hand, all 
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the toxins activated AMPK, and antimycin A failed to dephosphorylate CRTC2 
(Fig.3-8C). 
 
 
Fig.3-8. Pterosin B and antimycin A specifically disrupt RORα–SRC2. 
(A) The mRNA expression of gluconeogenic genes in AML-12 cells that had been treated with 
forskolin (Fsk, 10 μM) in the presence of various respiratory toxins, rotenone (0.3 μM), 
antimycin A (3 μM), and oligomycin (0.3 μM) for 2 h was measured using quantitative PCR (n 
= 3). Means and s.d. are shown. *: p < 0.05, **: p < 0.01. (B) SRC2-dependent activation of 
RORα was evaluated by reporter assay using the RORα LBD. Fsk (10 μM) was used to enhance 
RORα–SRC2-mediated transcription activity. (C) RORα–SRC2 interaction was evaluated by 
immunoprecipitation. 
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3-3. Discussion 
 
In this chapter, it has been identified that pterosin B strongly repressed G6pc 
expression induced by RORa-SRC2 in the cAMP signaling.  
Oligomycin (the complex V inhibitor) is often used as a positive control to activate 
AMPK, followed by a suppression of gluconeogenesis (11,12). In our control 
experiments, apparently both rotenone (the complex I inhibitor) and oligomycin 
activated AMPK and suppressed gluconeogenic programs associated with Ppargc1a, 
Pck1, and G6pc gene expressions. However, pterosin B and antimycin A (the complex 
III inhibitor) activated AMPK but upregulated Ppargc1a and Pck1 gene expressions. 
Both pterosin B and antimycin A interrupted the formation of the RORa-SRC2 
complex induced by cAMP, suggesting multiple targets of pterosin B in gluconeogenic 
programs including coenzyme Q and the RORa-SRC2 complex. 
Using pterosin B and antimycin A, an association between OXPHOS and the regulation 
of RORa was identified. The impairment of complex III activities or the accompanying 
phenomenon of reduced coenzyme Q accumulation specifically suppressed G6pc 
expression by disrupting the RORaeSRC2 complex formed by cAMP. Recently, 
metformin has also been found to lower Src2 expression levels followed by a reduction 
in G6pc expression (13). Although rotenone (a complex I inhibitor) also suppressed 
G6pc expression in our study, it did not alter the SRC2 levels or RORaeSRC2 
interaction, suggesting that RORa senses a variety of dysregulation in energy 
homeostasis by different mechanisms, and SRC2 contributes to a part of RORa 
pathways in gluconeogenic regulation. 
Hsu et al. (1) have reported that prolonged treatment with pterosin A causes 
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hypoglycemic effects in mice and glycogen accumulation in H4IIE hepatoma cells. The 
activation of AKT by pterosin A is the proposed mechanism by which glycogen 
synthesis is stimulated through GSK-3b inactivation. On the other hand, G6Pc 
deficiency in humans also causes excess glycogen storage, which is characterized by 
hypoglycemia and glycogen accumulation in the liver (7). Similar phenotypes are 
observed in SRC2- or ROR-deficient mice (5). These evidences suggest that pterosin A- 
and B-mediated hypoglycemic effects in mice may be the result of a lowered G6pc 
expression in hepatocytes.  
In conclusion, the present results demonstrate that pterosin B has multiple targets in 
the regulation of hepatic gluconeogensis, including coenzyme Q in RORa-SRC2 
signaling. 
 
 
 
 
Fig.3-9. Mechanism by which pterosin B regulates hepatic gluconeogenesis in a 
SIK3-independent manner. 
60 
 
3-4. Reference  
 
1. F.L. Hsu, C.F. Huang, Y.W. Chen, et al., Antidiabetic effects of pterosin A, a 
small-molecular-weight natural product, on diabetic mouse models, Diabetes 62 
(2013) 628-638. 
2. D.J. Kojetin, T.P. Burris, REV-ERB and ROR nuclear receptors as drug targets, Nat 
Rev Drug Discov 13 (2014) 197-216. 
3. A.M. Jetten, Retinoid-related orphan receptors (RORs): critical roles in development, 
immunity, circadian rhythm, and cellular metabolism, Nucl Recept Signal 7 
(2009) e003. 
4. M. Ermisch, B. Firla, D. Steinhilber, Protein kinase A activates and phosphorylates 
RORalpha4 in vitro and takes part in RORalpha activation by CaMK-IV, 
Biochem Biophys Res Commun 408 (2011) 442-446. 
5. A.R. Chopra, J.F. Louet, P. Saha, et al., Absence of the SRC-2 coactivator results in a 
glycogenopathy resembling Von Gierke's disease, Science 322 (2008) 
1395-1399. 
6. N. Kumar, D.J. Kojetin, L.A. Solt, et al., Identification of SR3335 (ML-176): a 
synthetic RORalpha selective inverse agonist, ACS Chem Biol 6 (2011) 
218-222. 
7. R. Froissart, M. Piraud, A.M. Boudjemline, et al., Glucose-6-phosphatase deficiency, 
Orphanet J Rare Dis 6 (2011) 27. 
8. P. Lau, R.L. Fitzsimmons, S. Raichur, et al., The orphan nuclear receptor, RORalpha, 
regulates gene expression that controls lipid metabolism: staggerer (SG/SG) 
mice are resistant to diet-induced obesity, J Biol Chem 283 (2008) 18411-18421. 
9. J.K. Byun, Y.K. Choi, Y.N. Kang, et al., Retinoic acid-related orphan receptor alpha 
61 
 
reprograms glucose metabolism in glutamine-deficient hepatoma cells, 
Hepatology 61 (2015) 953-964. 
10. S. Dasgupta, N. Putluri, W. Long, et al., Coactivator SRC-2-dependent metabolic 
reprogramming mediates prostate cancer survival and metastasis, J Clin Invest 
125 (2015) 1174-1188. 
11. M.R. Owen, A.P. Halestrap, The mechanisms by which mild respiratory chain 
inhibitors inhibit hepatic gluconeogenesis, Biochim Biophys Acta 1142 (1993) 
11-22. 
12. W. Hao, C.P. Chang, C.C. Tsao, et al., Oligomycin-induced bioenergetic adaptation 
in cancer cells with heterogeneous bioenergetic organization, J Biol Chem 285 
(2010) 12647-12654. 
13. A. Madsen, O. Bozickovic, J.I. Bjune, et al., Metformin inhibits hepatocellular 
glucose, lipid and cholesterol biosynthetic pathways by transcriptionally 
suppressing steroid receptor coactivator 2 (SRC-2), Sci Rep 5 (2015) 16430. 
 
 
 
 
 
 
 
 
 
 
62 
 
Summary 
  
Hepatic gluconeogenic programs are regulated by a variety of signaling cascades. 
Glucagon-cAMP signaling is the main initiator of the gluconeogenic programs, 
including G6pc gene expression. In this work, it has been demonstrated that SIK3 has 
important roles on hepatic gluconeogenesis. To examine the cell autonomous actions of 
SIK3, screenning of small compounds suppressing SIK3 signaling cascades was 
conducted. As the result, pterosin B was identified as SIK3 signaling inhibitor. Pterosin 
B inactivated SIK3 via the activation of PHKG2, resulting in up-regulation of G6pc 
expression even in the absence of cAMP. In this work, however, it was noticed that 
once cAMP signaling was initiated, pterosin B became a strong repressor of G6pc 
expression. The search for associated transcription factors for pterosin B actions 
revealed that RORa-SRC2 complex on the G6pc promoter was the target. Meanwhile, 
pterosin B impaired the oxidation-reduction cycle of coenzyme Q in mitochondrial 
OXPHOS; and antimycin A, an inhibitor of coenzyme Q: cytochrome c-oxidoreductase 
(termed mitochondrial complex III), also mimicked pterosin B actions on RORa-SRC2 
signaling. Although other respiratory toxins (rotenone and oligomycin) also suppressed 
G6pc expression accompanied by lowered ATP levels following the activation of 
AMPK, minimal or no effect of these other toxins on RORa-SRC2 activity was 
observed. These results suggested that individual components in OXPHOS 
differentially linked to different transcriptional machineries for hepatic gluconeogenic 
programs, and the RORa-SRC2 complex acted as a sensor for oxidation-reduction cycle 
of coenzyme Q and regulated G6Pc expression. This was a site disrupted by pterosin B 
in gluconeogenic programs.  
63 
 
 In this work, it has been identified that not only SIK3 but also RORa-SRC2 as a sensor 
for oxidation-reduction cycle of coenzyme Q could be new targets of diabetes treatment. 
Screening further compounds regulating these targets is needed. 
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Experimental Section 
 
Sik3-/- Mice 
Embryonic stem cells derived from a C57BL/6N strain (RENKA) were used with the 
Sik3-/- mice. After mating the mice with C57BL/6J mice (CLEA Japan, Tokyo, Japan) 
for 3 generations, mouse colonies were expanded for experiments under chow and 
high-fat-diet feeding. After 7 generations of cross breeding, mice colonies were used for 
cholesterol and cholic acid experiments. Sik3+/2 mice are now supplied by JCRB 
Laboratory Animal Resource Bank at the National Institute of Biomedical Innovation 
(No. nbio157). Information about SIK1-KO, SIK2-KO are described in (13,15), 
respectively. SIK1-KO mice were mated with C57BL/6J for six generations. The 
experimental mouse protocols were approved by the ethics committee of the National 
Institute of Biomedical Innovation (assigned No.DS20-56, 20-77, DS23-37, DS25-54). 
The animals were maintained under standard conditions of light (0800–2000) and 
temperature (23uC, 50% humidity). For tissue isolation, all mice were fasted for 4 h and 
then sacrificed within 61 h of lights out. The chow diet, MF, was purchased from 
Oriental Yeast (Tokyo, Japan). The high-sucrose (20% cal), high-fat (60% cal), and 
high-fat (45% cal)/high-sucrose (20% cal) diets were obtained from Research DIET Inc. 
(NJ,USA). The pre-fasting periods for the glucose tolerance test (GTT), insulin 
tolerance test (ITT), and lactate tolerance test (LTT) were 4, 2, and 24 h, respectively. 
We administered 1.5 g/kg glucose, 36 mg/kg insulin, and 1.5 g/kg lactate 
intraperitoneally for these tests, respectively. 
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Reagents  
Forskolin (Fsk), dexamethasone, glucose oxidase, 4-Aminoantipyrine, 
N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline, sodium salt (TOOS), 
horseradish peroxidase, oligomycin, 1-propanol, NaBH4 and mannitol were purchased 
from WAKO Pure Chemicals (Osaka, Japan). Sodium pyruvate solution, oxidized 
coenzyme Q10, rotenone, carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP), 
antimycin A, 2-deoxyglucose (2-DG), and D-glucose were obtained from 
Sigma-Aldrich (St. Louis, USA). Sodium malonate solution and trifluoroacetic acid 
(TFA) were obtained from NACALAI TESQUE, Inc (Kyoto, Japan).  HG9-91-01 was 
obtained from MedChem Express (Monmouth Junction, NJ, USA). Halo-tag expression 
plasmids for phosphorylase kinase gamma 2 (PHKG2) and other kinases and 
phosphatases were purchased from Promega (Madison, WI, USA). The anti-AMPK, 
anti-phospho-AMPK, and anti-phospho-CREB antibodies were from Cell Signaling 
(Boston, MA, USA), the anti-CREB antibody was from GenScript Corp. (Piscataway, 
NJ, USA), the anti-GAPDH antibody was from WAKO (Tokyo, Japan), and 
anti-PHKG2 antibody was obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, 
USA). SRC2 and RORα were obtained from Bethyl Laboratories Inc. (Montgomery, 
TX), Santa Cruz Biosciences Inc. (Dallas, Texas), respectively. Anti-pSIK3 (pT163) 
was created against the KLH-conjugated peptide (CSNLFTPGQLLK(pT)W, pT: 
phospho-Thr) in rabbits and purified with the same peptide. CRTC2 protein was 
separated on an 8% linear polyacrylamide gel, and other proteins were on 4 - 20% 
gradient gels. AML-12 (alpha mouse liver-12) cells from American Type Culture 
Collection were cultured in Dulbecco's Modified Eagle Medium (DMEM)-Ham’s F-12 
medium supplemented with 10% fetal bovine serum (FBS) and an insulin, transferrin, 
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and selenium supplement (ITS, Thermo Fisher, Carlsbad, CA, USA).  
Information about the knockout (KO) mice, SIK1-KO, SIK2-KO, and SIK3-KO are 
described in (13,15,18), respectively. SIK1-KO mice were mated with C57BL/6J for six 
generations. The experimental mouse protocols were approved by the ethics committee 
of the National Institute of Biomedical Innovation (assigned No.DS20-77, DS23-37, 
DS25-54). The animals were maintained under standard conditions of light (on: 08:00 – 
off: 20:00) and temperature (23 °C, 60% humidity). The kinase inhibitor (~90 
compounds) libraries were from Enzo Life Science (Farmingdale, NY), and the 
unannotated compounds (~2000) in the Molport libraries were purchased from Namiki 
Shouji (Tokyo, Japan). Flavonoids (~50) and other natural compounds (~150) were 
described in (24,25). Pterosin B was extracted from Pteridium aquilinum (total 100 kg, 
wet) after soaking in 0.1% sodium bicarbonate at 70 °C overnight. The ingredients in 
the P. aquilinum chloroform/hexane (1:4) extract were separated by silica gel and 
charcoal column chromatography, and pterosin B was crystallized in chloroform by 
increasing the hexane content. Finally, we got 3 g of pterosin B whose purity was 
confirmed by nuclear magnetic resonance. Synthetic pterosin B (racemic) was obtained 
from Intelium Crop. (Tokyo, Japan).  
 
Primary hepatocytes-  
Hepatocytes were isolated from mice as described previously (23). Briefly, under 
isoflurane anesthesia, the mouse livers were perfused with Hanks’ balanced salt solution 
(HBSS) which contained 0.5 mM EGTA, followed by perfusion with Liver Digest 
Medium (Thermo Fisher). Isolated hepatocytes were cultured in DMEM supplemented 
with 10% FBS, 100 nM insulin, and 1 μM dexamethasone (1×hepatocyte medium). 
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Before the treatments, the hepatocytes were incubated with DMEM supplemented with 
1% FBS, 10 nM insulin, and 0.1 μM dexamethasone (0.1×hepatocyte medium) for 12 h.  
 
DNA constructs and site-directed mutagenesis-  
A cDNA fragment for mouse MEF2C was amplified by means of PCR using primers 
5’-TTTTGGATCC(BamHI)ATGGGGAGAAAAAAGATTCAGAT and 
5’-TTTTTGCGGCCGC(NotI)TCATGTTGCCCATCCTTCAGAGA, digested with 
BamHI/NotI and ligated into the pM2 vector. The mammalian expression vector, 
pCMVsport6, containing full-length mCRTC2 (IMAGE: 5345301) cDNA, was 
purchased from Invitrogen. cDNA was digested with BamHI-NotI, and the TORC2 
cDNA fragments was ligated into the BamHI–NotI site of a GFP expression vector 
pEGFP-C for cytochemical studies and a pM vector (Gal4-fusion) for reporter assays. 
The SIK3 mutants (S493A, T411A, and the double Ala mutant (DA)) were constructed 
by site-directed mutagenesis using pTarget-hSIK3 plasmids and the following primers: 
for S493A 
(5'-CCCTTGGCCGGAGGGCTGCAGATGGAGGAGCCAAC/5’-GTTGGC  
TCCTCCATCTGCAGCCCTCCGGCCAAGGG), and for T411A 
5’-TTGTCAATGAGGAGGCATGCCGTGGGTGTGGCTGACCCA/5’-TGGGTCAG
CCACACCCACGGCATGCCTCCTCATTGACAA). The SIK3 DA mutant was 
constructed by using pTarget-hSIK3 S493A as the template with the primers for T411A. 
To prepare an adenovirus vector for SIK3 (WT, DA), the SIK3 cDNA fragments were 
amplified by PCR with the attB primers. The amplified products were then constructed 
into pDONR221 vectors by using BP clonase enzyme mix (Thermo Fisher). The 
resultant cDNAs were finally cloned into pAd/DMV/V5-DEST Gateway vectors using 
68 
 
LR clonase enzyme mix (Thermo Fisher). To screen the SIK3 inhibitory compounds, 
we constructed the LexA reporter assay system. A DNA fragment containing 3×LexA 
elements was prepared by annealing the oligonucleotides 
5’-GATCTACTGTATATATATACAGTAGAGTACTGTATATATATACAGTACAC
TACTGTATATATATACAGTA/5’-AATTTACTGTATATATATACAGTAGTGTAC
TGTATATATATACAGTACTCTACTGTATATATATACAGTA) and the fragment 
was ligated into the Bgl II / EcoR I site of the Renilla-Luc internal reporter vector 
(pRL-TK). To prepare the LEXA-CRTC2 expression vector, a DNA fragment for 
LEXA DNA-binding domain was amplified by PCR with primers 
(5’-GCAAAAAGCTAGATCATGAAAGCGTTAACGGCCAGGCAA/5’-ACCATAA
TGAGAGTCCAGCCAGTCGCCGTTGCGAA) and E. coli genome DNA. An 
In-Fusion HD Cloning Kit (Clontech, Mountain View, USA) was used to replace the 
DNA fragment for the GAL4 DNA-binding domain in the pM-CRTC2 vector with the 
LEXA fragments in pM-CRTC2. The HEK293 cells were placed into 96-well 
white-bottom plates and transfected with the SIK3 expression vectors (WT or its empty 
vector; 5 ng), DNA-binding domain-linked expression vectors (pM-MEF2C and 
pMLexA-CRTC2; 5 ng), pTAL-GAL4 (20 ng), and pRL-LexA (20 ng) per well, using 
Lipofectamine 2000 (Thermo Fisher). To measure the reporter activity, we used the 
Dual-Luciferase Reporter Assay System (Promega). The cells were lysed with 10 μL of 
passive lysis buffer, and all of the lysate was used for the assay. 
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Quantitative real-time PCR analysis 
The total RNA was extracted using an EZ1 RNA Universal Tissue Kit (Qiagen, Venlo, 
Netherlands), and the cDNA was synthesized using a ReverTra Ace qPCR RT Master 
Mix (TOYOBO, Kyoto, Japan). PCR amplification was performed using an EXPRESS 
SYBR GreenER (Thermo Fisher). Primers used in this study were Pgc1a 
(5’-GCGAACCTTAAGTGTGGAAC/5’-CACCACGGTCTTGCAAGAGG), Pepck 
(5’-AGAACAAGGAGTGGAGACCG/5’-GCTTCATAGACAAGGGGGAC), G6pc 
(5’-CGCAGCAGGTGTATACTATG/5’-CCCAGAATCCCAACCACAAG), and Tbp 
(5’-GAGCTCTGGAATTGTACCGC/5’-TGTGCACACCATTTTTCCAG). Levels of 
gluconenogenic mRNA were normalized by Tbp mRNA.  
 
Reporter assay 
HEK293 and AML-12 cells were transfected with the SIK3 expression vectors (pTarget 
hSIK3 WT, T411A, S493A, T411A/S493A [DA] or its empty vector; 50ng), GAL4 
DNA-binding domain-linked expression vectors (pM-MEF2C, pM-CRTC2 or its empty 
vector; 50ng), pTAL-GAL4 (150ng), and the Renilla-Luc internal reporter 
(pRL-(Int-)TK, 50ng) using Lipofectamine 2000 reagent (Thermo Fisher). To measure 
reporter activity, we used the Dual-Luciferase Reporter Assay System (Promega). The 
cells were lysed with 100 μL of passive lysis buffer, and 10 μL was used for the assay. 
The activities of firefly luciferase were normalized by those of Renilla luciferase. The 
reporter activity measurement was performed as described above. The cells were lysed 
with 100 μL of passive lysis buffer, and 10 μL was used for the assay. The activities of 
firefly luciferase were normalized by those of Renilla luciferase. To construct vectors 
for miRNA(s) against PHKG2, double-stranded oligonucleotides (No. 1: 5′- 
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TGCTGAGAATGTGCATCTCTCGCCGTGTTTTGGCCACTGACTGACACGGCGA
GATGCACATTCT/5′-CCTGAGAATGTGCATCTCGCCGTGTCAGTCAGTGGCCA
AAACACGGCGAGAGATGCACATTCTC and No. 2: 
5′-TGCTGTCCAGTAGAGACCTCATGATGGTTTTGGCCACTGACTGACCATCA
TGATCTCTACTGGA/5′-CCTGTCCAGTAGAGATCATGATGGTCAGTCAGTGGC
CAAAACCATCATGAGGTCTCTACTGGAC) were introduced into the 
pcDNA6.2-GW/EmGFP-miR vector (Life Technologies), and adenoviruses were 
prepared by the Gateway system. Knockdown of PHKG2 protein in AML-12 cells was 
achieved by 2 times infection / transformation with 2 days interval. 
The G6pc luciferase gene including the promoter sequence was amplified with mouse 
genomic DNA and the primers (G6pc prom F/R in Supplementary Materials). PCR 
products were cloned into the pGL3 vector. The G6pc mutant was constructed by 
site-directed mutagenesis using pGL3 G6pc plasmids and the primers (G6pc prom MutF 
and MutR). Halo-tagged RORα and SRC2 expression plasmids were purchased from 
Promega (Madison, WI). The plasmids were reconstructed into the pcDNA3.2 vector. 
GAL4-RORα/β/γ cDNA fragments were amplified with the following primers: RORα 
F/R, RORβ F/R, and RORγ F/R in Supplementary Materials and then ligated into the 
pM vector (the Bam HI- Not I site that was created in a previous study). The AML-12 
cells were plated onto 24-well-plates and transfected with pGL3-G6pc WT, mutant, or 
empty vector (200 ng): Runilla-Luc internal reporter [pRL-(Int) TK, 50ng], 
pcDNA3.2-RORα (50 ng), and pcDNA3.2-SRC2 (50 ng). The reporter activity was 
measured using Dual-Luciferase Reporter Assay System (Promega). 
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Glucose production and cAMP measurement  
Primary hepatocytes were seeded on a 24-well plate (1.0×106) and incubated in an 
1×hepatocyte medium for 3 h and then in an 0.1×hepatocyte medium for 12 h. The 
AML-12 cells were plated in 24-well plate (1.0×106) and incubated in DMEM/F-12 
medium for 72 h (with medium change every 24 h) to increase the cellular lipid droplets. 
After the medium replacement with 0.1×hepatocyte medium, the cells were further 
cultured for 12 h. The glucose production assay was performed as described (22). 
Briefly, the cells were washed with phosphate buffer saline followed by adding 
300 μL of assay medium (DMEM without glucose or glutamate containing 1 mM 
sodium pyruvate, 10 mM lactate, and 100 nM dexamethasone) containing the 
compounds (Fsk etc.) per well. After approximately 0-8 h of incubation, the assay 
medium was harvested and centrifuged at 12,000 rpm for 10 min. Then, 20 μL of the 
supernatant was used for the assay. To measure the glucose levels, 180 μL of reaction 
buffer (50 mM sodium phosphate (pH 7.0), 1 U/mL glucose oxidase, 0.1 U/mL horse 
radish peroxidase, 50 μM 10-acetyl-3,7-dihydroxyphenoxazine, ADHP) was added to 
each well of a 96-well black plate and incubated at room temperature for 30min. The 
fluorescence at 590 nm was measured with excitation at 535 nm. The AML-12 cells 
were placed into a 96-well plate at a density of 2.0×104. The pGloSensor-22F cAMP 
Plasmids (Promega) were transfected into the cells using Lipofectamine 2000. The 
cAMP levels were detected with chemiluminescence using GloSensor cAMP Reagent 
(Promega). 
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Purification of SIK3 and in vitro kinase activity  
The pEBG-hSIK3 WT vector was transfected into the HEK293 cells. After 36 h of 
transfection, the cells were lysed with IP lysis buffer (50 mM Tris-HCl (pH 8.0), 5 mM 
EDTA, 5 mM EGTA, 2 mM DTT, 50 mM glycerol 3-phosphate, 50 mM NaF, 1 mM 
NaVO4, 0.5% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 μg/mL leupeptin, 
and 14 μg/mL aprotinin) and incubated with glutathione sepharose 4B (GE Healthcare, 
Waukesha, USA) at 4 °C for 15 min. The protein complexes were washed with IP lysis 
buffer and eluted with 10 mM of glutathione. Aliquots of purified SIK3 were subjected 
to an in vitro kinase assay and Western blot analyses. Adenoviruses of hSIK3 WT and 
DA was transfected to AML-12 cells. After the stimulation with Pterosin B and Fsk, the 
cells were lysed with 1 mL of IP lysis buffer and incubated with Protein G Sepharose 
(GE Healthcare) containing anti-SIK3 antibody at 4 °C for 1 h. Purified SIK3 was 
eluted with 100 μL of 3×SDS and detected by western blot analyses. The purified SIK3 
enzyme was incubated with coumarin-labeled CRTC2 peptides and compounds in 40 
μL of reaction buffer (5 mM Tris-HCl (pH 7.4), 1 mM ATP, 1 mM DTT, 5 mM MgCl2). 
The reactions were performed at 25 °C for 1 h and were stopped by the addition of 40 
μL of 3×SDS sample buffer. The phosphorylated peptide was separated by 
electrophoresis on a 1.5% agarose gel in 50 mM Tris–borate buffer (pH 8.5) and 
visualized by ultraviolet light (28). The PHKG2 enzyme was also prepared by the same 
methods as for SIK3 and incubated with coumarin-labeled SIK3 T411 peptide 
(KKLSMRRHTVGVADP) or S493 peptide (KKPLGRRASDGGANI) in 40 μL of the 
reaction buffer (5 mM Tris-HCl [pH 6.8], 1 mM ATP, 1 mM DTT, 5 mM MgCl2). 
The phosphorylated peptide was separated on the agarose gel in 50 mM Tris–acetate 
buffer (pH 3.5). 
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Glycogen measurement  
AML-12 cells were lysed in 0.1 M sodium citrate buffer (pH = 4.2) supplemented with 
60 mM NaF, and the supernatants were recovered by centrifugation at 14,000 g for 5 
min. The concentration of glycogen was measured using the EnzyChrom Glycogen 
Assay Kit (BioAssay Systems, Hayward, CA, USA). Reagents for Periodic acid–Schiff 
(PAS) stain were obtained from Mutokagaku Co. Ltd. (Tokyo, Japan). 
 
Cellular ATP and NADH levels 
AML-12 cells were plated onto 96-well plates. The following day, cells were pre-treated 
for 1 h with DMEM (free of glucose, pyruvate, and glutamine). The medium was 
changed for 1 h to a reaction medium containing pterosin B (300 µM) ± 2 mM glucose, 
2 mM pyruvate, and 2-DG. ATP was measured using an ATP measurement reagent 
(TOYO B-net, Tokyo, Japan). NADH was measured using the Cell Counting Kit-8 or 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-assay Kit (Dojin, 
Tokyo, Japan). 
 
Isolation of mitochondria from AML-12 cells 
AML-12 cells were plated into 15-cm dishes at a density of 2 × 106. After 2 days in 
culture, cells were harvested using 5 ml of extraction buffer (10 mM HEPES, 200 mM 
mannitol, 70 mM sucrose, and 1 mM EGTA) followed by homogenization in a 10-mL 
Dounce homogenizer. The homogenized cells were centrifuged at 600 × g for 5 min at 
4°C. The supernatant was then was centrifuged at 11,000 × g for 10 min. The 
supernatant was removed, and pellets were washed with 1 mL of reaction buffer (300 
mM mannitol, 10 mM KCl, 5 mM MgCl2, 10 mM potassium phosphate, and 10 mM 
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Tris-HCl with pH 6.8). After centrifugation at 11,000 × g for 10 min, pellets were 
re-suspended in 500 μL of reaction buffer containing bovine serum albumin (2 mg/mL). 
 
Mitochondrial ATP production assay 
One milligram of mitochondria was mixed with the reaction buffer containing 100 µM 
ADP, substrates (100 µM pyruvate and 100 µM malate as complex I substrate, 100 µM 
succinate as complex II substrate, and 500 µM ascorbic acid plus 125 µM TMPD for the 
reduction of cytochrome C), and inhibitors (500 µM pterosin B, 50 µM rotenone as 
complex I inhibitor, 1 mM malonic acid as complex II inhibitor, and 100 µM 
oligomycin as complex V inhibitor). The mixture was incubated at 25°C for 10 min. 
Five microliters of the mixture was added to 30 µL of ATP measurement reagent (see 
above) followed by the addition of 25 µL of water. 
 
HPLC analysis of coenzyme Q10 from HEK293 cells 
Mouse cells (such as AML-12) have coenzyme Q9, and human cells have coenzyme Q10. 
Because we could obtain only coenzyme Q10 standards, human embryonic kidney 293A 
cells (HEK293A, Thermo Fisher Scientific) were used. These cells were plated onto 
10-cm dishes and were incubated for 1 h with pterosin B the following day. Washed 
cells were harvested in 1 mL of trypsin and centrifuged at 1500 rpm for 10 min. The cell 
pellets were suspended in PBS, followed by lysis with 1.5 mL of ethyl acetate. The 
extracts were centrifuged at 1500 rpm for 10 min, and the upper layer was transferred 
into new tubes. The organic layer was then dried and dissolved in 20 µL of 1-propanol. 
Ten microliters was used for HPLC analysis [1]. 
The oxidized form of coenzyme Q10 was reduced with NaBH4 to yield coenzyme 
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Q10H2. Briefly, 200 μL of 100 μM coenzyme Q10 was reacted with 5 μL of 100 μM 
NaBH4 at room temperature in a dark place. Coenzyme Q10H2 extraction was performed 
as previously described and dissolved in 100 μL of 1-propanol [2]. Reduced and 
oxidized forms of coenzyme Q10 were separated by HPLC. HPLC operating conditions 
were established as follows: COSMOSIL 5C18-MS-II, 4.6 mm × 100 mm (NACALAI 
TESQUE, Inc); 20% 1-propanol, 0.05% TFA in methanol as the mobile phase; isocratic 
mode at a flow rate of 1 mL/min; and UV detection at 275 nm. 
 
Measurement of oxygen consumption  
Oxygen consumption was measured using the Seahorse XF24 Flux Analyzer (Seahorse 
Bioscience, Billerica, USA). AML-12 cells were plated onto 24-well XF24 cell culture 
plates at a density of 3 × 105. The following day, the culture medium was changed to the 
assay medium (DMEM) containing 2.5 mM glucose, 1 mM pyruvate, and 0.5 mM 
glutamine. Mitochondrial function was determined using a sequential injection of 
pterosin B, oligomycin, FCCP, and rotenone plus antimycin A. 
 
Western blotting and immunoprecipitation (IP) 
AML-12 cells that had been plated onto 6-well plates were stimulated with inhibitors 
and forskolin for 1 h were lysed with 1 mL of IP lysis buffer (50 mM Tris-HCl with pH 
8.0, 5 mM EDTA, 5 mM EGTA, 2 mM DTT, 50 mM glycerol 3-phosphate, 50 mM NaF, 
1 mM NaVO4, 0.5% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 μg/mL 
leupeptin, and 14 μg/mL aprotinin) [3] and incubated with Protein G Sepharose (GE 
Healthcare) containing RORα antibody at 4°C for 1 h. Purified RORα was eluted with 
50 µL of 3 × SDS and detected by western blot analysis. 
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Statistical analyses  
Data from each group were characterized by the mean±SD. Student’s t-test was used to 
assess all experimental data in Microsoft Excel. 
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Abbreviation 
 
SIK: Salt-inducible kinase 
AMPK: 5′-AMP-activated protein kinase  
cAMP: cyclic adenosine monophosphate 
CREB: cAMP responsive element binding protein 
CRTC: CREB-regulated transcription coactivator 
HDAC: histone deacetylase 
PKA: cAMP-activated protein kinase 
MEF2: myocyte enhancer factor 2 
Pepck: phosphoenolpyruvate carboxykinase 
G6pc: glucose-6-phosphatase catalytic subunit  
Pgc1a: peroxisome proliferator-activated receptor gamma coactivator 1α 
AML-12: alpha mouse liver-12 
DMEM: Dulbecco's Modified Eagle Medium 
ITS: insulin, transferrin, and selenium supplement 
Fsk: forskolin  
STS: staurosprine 
fLuc: firefly luciferase 
rLuc: Renilla luciferase 
GFP: green fluoresce protein 
LKB1: liver kinase B1 
CaMK: Ca2+/calmodulin-dependent protein kinase 
PP1CA: protein phosphatase 1, catalytic subunit, alpha isozyme 
78 
 
PP2CA: protein phosphatase 2, catalytic subunit, alpha isozyme 
Cn: protein phosphatase 3, catalytic subunit, alpha isozyme 
PDK2: pyruvate dehydrogenase kinase, isozyme 2 
PDK4: pyruvate dehydrogenase kinase, isozyme 4 
PDP1: pyruvate dehyrogenase phosphatase catalytic subunit 1 
PDP2: pyruvate dehyrogenase phosphatase catalytic subunit 2 
PHKG1: phosphorylase kinase, gamma 1 
PHKG2: phosphorylase kinase, gamma 2 
RORa: retinoic acid receptor-related orphan receptor alpha; 
SRC2: steroid receptor coactivator 2 
OXPHOS: oxidative phosphorylation 
FCCP: carbonilcyanide p-triflouromethoxyphenylhydrazone 
2-DG: 2-deoxyglucose 
TFA: trifluoroacetic acid 
ADP: adenosine 5'-diphosphate 
qPCR: quantitative real time PCR. 
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